Further, the outcomes of comprehensive pan‐cancer analysis on chemokine system, MHCs, immunostimulators and TIICs indicated that BCAT2 has significant immunosuppressive effects in a couple of cancer types, including bladder cancer (BLCA), breast cancer (BRCA), kidney renal papillary cell carcinoma (KIRP), pancreatic adenocarcinoma (PAAD), sarcoma (SARC) and thyroid carcinoma (THCA) (Figure S2A,B, Supporting Information). Here, BCAT2 is linked to bladder transitional cell carcinoma.